शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
SANDUMANSESANDUR MANG & IRON ORES L· Ferrous MetalsMediumNeutral
Announced Wed, 4 Nov, 2026 · 14:12 IST

Q2FY27 consolidated net profit up 88% as expansion plans advance

Multi-year targets disclosedInvestor Communications View source PDFExplain this filing

SANDUMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+8.3%Reaction day
₹164.98
prior close
₹178.62
announcement price
In-mkt
timing
Nifty Microcap 250market+2.2%+6.1% vs market
Iron & Steel peers, median of 10sector+2.1%+6.2% vs sector

On the reaction day the stock moved 6.1 pts more than Nifty Microcap 250 and 6.2 pts more than its Iron & Steel peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.5
10m
-0.1
15m
+0.0
30m
-0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+8.3+2.2+6.1+2.1+6.2
Next day
+8.3+3.3+5.0+3.8+4.5
2d
+7.8pendingpending+3.5+4.2
3d
—————
4d
—————
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Iron & Steel peers, median of 10Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2FY27 consolidated total income was ₹1,519 crore, earnings before interest, tax, depreciation and amortisation were ₹391 crore, and net profit was ₹261 crore. These rose 22%, 37% and 88% year on year. First-half net profit rose 60% to ₹489 crore; cash was ₹630 crore. Plans include a ₹220 crore Punjab steel expansion to 1.70 lakh tonnes a year, a ₹390 crore MedTech unit for December 2027 and a Q2FY28 beneficiation plant.

Likely market impact

The strong quarter may support the stock, but new projects add capital spending, execution and approval risks.